Finance
S&P 500 7,757.17 +44.60 +0.58% Dow 52,856.09 +360.19 +0.69% Nasdaq 26,702.86 +278.04 +1.05% NYSE Composite 24,253.12 +62.52 +0.26% Russell 2000 2,781.02 +7.60 +0.27% VIX 16.68 -0.63 -3.64%

BIVI · BioVie Inc. Class A

NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD

BioVie Inc (BIVI)

NASDAQ NMS - GLOBAL MARKET Biotechnology
Move probability → Options chain →
$1.25 -0.01 (-0.79%)
● At close: October 21 at 4:00:00 PM EDT
$1.24 -0.02 (-1.59%)
🌙 Overnight: 11:30:53 PM EDT
DAY'S RANGE $1.25
$1.16 $1.27
52-WEEK RANGE $1.25
$0.82 $3.79

What's happening

Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.

Key Statistics

Market Cap$10.0M
P/E (TTM1)—
EPS2 (TTM)$-3.15
Div Yield—
Beta30.85
Volume4,473
Open1.17
Prev Close1.26
Bid / Ask1.06 / 0.00
Next Earnings 2026-11-09

Analyst Recommendations

Strong buy 2 Buy 5 Hold 1 Sell 0 Strong sell 0

Aggregate ratings for 2026-10-01 (8 analysts polled by Finnhub) — consensus count.

Performance Overview (Trailing returns vs S&P 500 benchmark)

YTD RETURN
BIVI +6.90%
vs S&P 500 -5.88%
1-YEAR RETURN
BIVI -37.69%
vs S&P 500 -52.25%
6-MONTH RETURN
BIVI -15.07%
3-MONTH RETURN
BIVI -3.88%

Valuation Measures & Ratios

Enterprise Value4$1.6M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book71.42
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-126.02%
Return on Assets (ROA9)-108.88%
Avg Volume (3M)3,331,030
Quarterly history (5 periods)
Measure Mar '26Dec '25Sep '25Mar '25Dec '24
Market cap $352.4K $303.5K $330.7K $587.0K $1.0M
P/E -0.02 -0.01 -0.02 -0.03 -0.04
Price/Book 0.02 0.02 0.01 0.03 0.04
ROE -123.12% -109.31% -76.80% -101.39% -115.93%
ROA -109.71% -93.58% -71.37% -89.70% -107.94%

Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).

Glossary — what these abbreviations mean
1. TTM
Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
2. EPS
Earnings per share — net income divided by diluted shares outstanding.
3. Beta
A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
4. EV (Enterprise Value)
Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
5. Forward P/E
Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
6. PEG Ratio
P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
7. Price / Book
Share price divided by book value (assets minus liabilities) per share.
8. ROE
Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
9. ROA
Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
10. MRQ
Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
11. YoY
Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.

Short Interest

Shares Short831,296
Change from Prior Settlement-20.53%
% of Float—
Days to Cover (Short Ratio)2.73

Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.

Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.

Price history

Events

Drag horizontally to zoom into a section; use Reset view to restore all observations.

Technical signal summary

Calculating from the latest year of daily price history…

Calculating…
Show Technical Analysis Breakdown ▾ 10 Indicators

Not investment advice — read several signals together.

Indicators None active

Add lines over the price chart or a panel below it. Your choices are saved on this device.

Starter sets
Trend
Oscillators
Volume/volatility
Loading chart…

History limited by data provider; markers are heuristics, not signals.

Peer and sector context

No reviewed peer group is available for this symbol.

Balanced evidence

A deterministic summary of sourced facts—not an AI verdict.

Potential strengths

  • Latest SEC filing is Form 8-K, filed 2026-09-14; review it for current changes and risks. SEC EDGAR ↗

Potential concerns

Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.

No accessible free API for these — links go to the source directly.

Morningstar Motley Fool MarketBeat

Financials

Income statement

Line item Mar '26Dec '25Sep '25Mar '25Dec '24Sep '24Mar '24Dec '23
Operating income -$5.4M -$6.3M -$5.3M -$3.0M -$7.3M -$4.1M -$7.7M -$8.8M
Net income -$5.3M -$6.1M -$5.1M -$2.8M -$7.1M -$4.2M -$8.1M -$8.4M
EPS (diluted) $-0.70 $-0.77 $-0.98 $-1.51 $-4.55 $-7.00 $-2.00 $-2.20
EPS (basic) $-0.70 $-0.77 $-0.98 $-1.51 $-4.55 $-7.00 $-2.00 $-2.20

Balance sheet

Line item Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24
Total assets $14.3M $17.5M $22.5M $26.8M $21.6M $24.7M $25.7M $21.2M
Total liabilities $4.0M $1.9M $3.2M $1.9M $2.6M $2.8M $1.8M $7.2M
Stockholders' equity $10.3M $15.6M $19.3M $24.9M $19.0M $21.8M $23.9M $14.1M
Total current assets $13.6M $16.9M $21.8M $26.0M $20.7M $23.7M $24.7M $20.2M
Total current liabilities $3.8M $1.7M $3.0M $1.6M $2.3M $2.5M $1.5M $6.8M
Cash & equivalents $9.0M $13.1M $20.5M $25.0M $17.5M $23.2M $24.4M $20.0M

Cash flow

Line item Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24
Operating cash flow -$4.1M -$7.4M -$4.4M -$3.0M -$5.6M -$1.3M -$8.6M -$3.6M
Investing cash flow — — — — — — — —
Financing cash flow $0 $0 $0 $10.5M $0 $0 $13.0M -$240.9K
Depreciation & amortization — — — — — — — —
Share-based compensation $256.7K $1.6M $197.3K $268.4K $352.8K $338.4K $385.3K $118.9K
Deferred income taxes — — — — — — — —

Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.

Institutional holders

SEC Form 13F filers holding BIVI as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.

Institutional ownership is not available for this symbol right now.

Insider activity

Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.

Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-02-16 to 2026-08-28

Recent transactions

  • Insiders have net bought 23,280 shares over the last 182 days, across 4 purchases and 0 sales.
  • Most recent: Palumbo Joseph M (Chief Medical Officer) — Open market purchase of 4,843 shares on 2026-08-28.

Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.

Insider purchases & sales, last 6 months

Purchases (open market)23,280 sh(4 txns)
Sales (open market)0 sh(0 txns)
Net Shares+23,280

Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.

Insider roster

NameTitleMost Recent TransactionDateShares
Palumbo Joseph MChief Medical OfficerOpen market purchase2026-08-284,843
Chappell Amy SuzonDirectorOpen market purchase2026-08-28727
KIM JOANNE WENDYChief Financial OfficerOpen market purchase2026-08-282,500
DO CUONG VPresident & CEOOpen market purchase2026-08-2715,210
ROGICH SIGMUNDDirectorGrant / award2024-11-2032,700
BERMAN RICHARD JDirectorGrant / award2024-11-2034,200

Recent transactions

DateInsiderTitleTransactionSharesPrice
2026-08-28Palumbo Joseph MChief Medical OfficerOpen market purchase 4,843$2.16
2026-08-28Chappell Amy SuzonDirectorOpen market purchase 727$2.16
2026-08-28KIM JOANNE WENDYChief Financial OfficerOpen market purchase 2,500$2.18
2026-08-27DO CUONG VPresident & CEOOpen market purchase 15,210$2.08
2025-08-07DO CUONG VPresident & CEOOpen market purchase 5,000—
2024-11-20ROGICH SIGMUNDDirectorGrant / award 32,700$0.00
2024-11-20BERMAN RICHARD JDirectorGrant / award 34,200$0.00

Recent SEC filings

Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.

Source: SEC EDGAR submissions · updated 2026-10-22 07:04 UTC

FiledFormReport periodOfficial filing
2026-09-148-K2026-09-11 View on SEC.gov →
2026-08-2842026-08-28 View on SEC.gov →
2026-08-2842026-08-28 View on SEC.gov →
2026-08-2842026-08-28 View on SEC.gov →
2026-08-2842026-08-27 View on SEC.gov →
2026-08-1310-K2026-06-30 View on SEC.gov →
2026-08-068-K2026-08-06 View on SEC.gov →
2026-05-1110-Q2026-03-31 View on SEC.gov →
2026-02-0610-Q2025-12-31 View on SEC.gov →
2026-01-0942026-01-05 View on SEC.gov →
2026-01-0942026-01-05 View on SEC.gov →
2026-01-0942026-01-05 View on SEC.gov →

Headlines about BIVI (BioVie Inc. Class A). Links open the publisher — we don’t host full articles.

SEC filings ↓

← Back to the full dashboard · My watchlist